Skip to main content

Table 1 Characteristics of the patients

From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

Characteristic Total (n = 38)
Age (years) 59.4 ± 9.2
Median (range) 60 (35, 79)
Sex, n (%)
Male 32 (84.2)
Female 6 (15.8)
ECOG performance status, n (%)
0 20 (52.6)
1 13 (34.2)
2 5 (13.2)
BCLC grade, n (%)
B 18 (47.4)
C 20 (52.6)
Hepatitis, n (%)
Hepatitis B 32 (84.2)
Hepatitis C 2 (5.3)
No 4 (10.5)
Maximum tumor size (cm) 3.75 (0.9, 15.1)
Tumor number, n (%)
Single 4 (10.5)
Multiple 32 (84.2)
Unknown 2 (5.3)
Child–Pugh grade, n (%)
A 37 (97.4)
B 1 (2.6)
Macrovascular invasion, n (%) 12 (31.6)
AFP ≥ 400 μg/L, n (%) 11 (28.9)
Comorbidity, n (%)
Hypertension 15 (39.5)
Diabetes Mellitus 4 (10.5)
Extrahepatic metastasis, n (%) 13 (34.2)
Prior local therapy, n (%)
Surgery 13 (34.2)
Ablation 20 (52.6)
TACE 36 (94.7)
Radiotherapy 6 (15.8)
Prior systemic therapy, n (%)
Sorafenib 33 (86.8)
Lenvatinib 1 (2.6)
Lenvatinib sequential to sorafenib 4 (10.5)
Follow-up (months), median (range) 5.6 (0.7, 17.0)
  1. ECOG Eastern Cooperative Oncology Group, BCLC Barcelona clinic liver cancer, AFP α-fetoprotein, TACE transarterial chemoembolization